English
Home > Products > 1H-pyrazolo[3,4-b]pyridine

China 1H-pyrazolo[3,4-b]pyridine Factory

Our growth depends within the innovative equipment, fantastic talents and repeatedly strengthened technology forces for 1H-pyrazolo[3,4-b]pyridine,CAS NO 1350653-26-7,1350653-26-7,Vericiguat intermediate,Vericiguat advance intermediate, Our aim will be to assistance shoppers comprehend their goals. We've been earning good endeavours to obtain this win-win scenario and sincerely welcome you to definitely sign up for us.
1H-pyrazolo[3,4-b]pyridine, We rely on high-quality materials, perfect design, excellent customer service and the competitive price to win the trust of many customers at home and abroad. 95%products are exported to overseas markets.

Related Products

Hot Products

  • Erythorbic Acid

    Erythorbic Acid

    Product Name:Erythorbic Acid
    Molecular Formula:C6H8O6
    Molecular Weight:176.12
    CAS Registry Number:89-65-6
  • (3S,6S)-(+)-3,6-Octanediol

    (3S,6S)-(+)-3,6-Octanediol

    Product Name:(3S,6S)-(+)-3,6-Octanediol
    Molecular Formula:C8H18O2
    Molecular Weight:146.23
    CAS Registry Number:136705-66-3
  • Celite

    Celite

    Product Name:Celite
    Molecular Formula:O2Si
    Molecular Weight:60.0843
    CAS Registry Number:61790-53-2
  • 1,3-Bicyclo[1.1.1]Pentanedicarboxylic Acid

    1,3-Bicyclo[1.1.1]Pentanedicarboxylic Acid

    Product Name:1,3-Bicyclo[1.1.1]Pentanedicarboxylic Acid
    Molecular Formula:C7H8O4
    Molecular Weight:156.14
    CAS Registry Number:56842-95-6
  • Ganirelix Acetate

    Ganirelix Acetate

    Product Name:Ganirelix Acetate
    Molecular Formula:C80H113ClN18O13
    Molecular Weight;1570.34
    CAS Registry Number;123246-29-7
  • Lifitegrast

    Lifitegrast

    Product Name:Lifitegrast
    Molecular Formula:C29H24Cl2N2O7S
    Molecular Weight;615.48
    CAS Registry Number;1025967-78-5
  • Related Blog
  • Reviews

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept